• Trial(s) for Transplantation

    Study Objective Contact
    A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration -controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus based regiMen (TRANSFORM) [LCID Study Number: 2014-080] The purpose of this study is to compare 2 maintenance treatment regimens in patients who undergo a kidney transplant to determine which treatment is best able to maintain good function of a transplanted kidney while causing the least number of side effects. Principal Investigator(s):
    Mohamed E. Akoad, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants [LCID Study Number: 2014-032] Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants Principal Investigator(s):
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-like 2 (LOXL2) in SUBJECTS WITH ADVANCED LIVER FIBROSIS but Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) GS-US-321-0105 [LCID Study Number: 2013-028] The purpose of this study is to see if the investigational drug, GS-6624, can reverse advanced liver fibrosis and prevent cirrhosis. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Amir A. Qamar, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) in SUBJECTS WITH COMPENSATED CIRRHOSIS Secondary to Non-Alcoholic Steatohepatitis (NASH) GS-US-321-0106 [LCID Study Number: 2013-026] The purpose of this study is to see if simtuzumab can reverse liver scarring and heal cirrhosis. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Amir A. Qamar, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    A Prospective Investigation Of Quality Of Life In Live Liver Donors [LCID Study Number: 2001-019] Questionnaire study of quality of life in live liver transplant donors Principal Investigator(s):
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-Free, Nulojix® (belatacept) Based Immunosuppression [LCID Study Number: 2015-045] This study is for patients undergoing kidney transplants. It will evaluate how often acute rejection of the transplanted organ occurs in patients who are taking different types of immunosuppressants. There will be two groups of patients in this study. One group, called the standard or control group, will receive the regular, standard of care treatment of immunosuppressant medication after their transplant. The second group, called the experimental group, will be put on a combination of immunosuppressant drugs that has not approved by the FDA: Thymoglobulin, steroids, and belatacept and everolimus (EVL). Each of these three drugs is approved by the FDA to act individually, but they are not approved to work together. Patients will know what group they have been assigned to. Patients enrolled in this study will be in active treatment for about 2 years, and then will be followed up for about 6 months after they stop treatment. Principal Investigator(s):
    Mohamed E. Akoad, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    Integrated Tissue and Clinical Data Bank for Bile Duct Cancers [LCID Study Number: 2013-022] Very little is known about what causes bile duct cancers. It is hoped that by studying tissue samples and clinical information from patients with bile duct cancers together, researchers may learn about factors that cause these cancers. Principal Investigator(s):
    Roger Jenkins, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco.
  • Make An Appointment

    (781) 744-2500
  • HRSA Award

    Health Resources and Services Administration (HRSA) Awards Lahey Clinic the Silver1 Medal of Honor for Organ Donation.